A Cross-Sectional Study For Evaluation of Kras and Braf Mutations By Reversedot Blot, Pcr-Rflp, and Allele-Specific Pcr Methods Among Patients With Colorectalcancer

Background: kras and braf genes are the biomarkers in colorectal cancer (crc)which play prognostic and predictive roles in crc treatment. nowadays, the selectionof rapid and available methods for studying kras and braf mutations in anti-egfrtherapy of patients suffering from crc plays a significant role. in this study, the mutationsof these two oncogenes were evaluated by different methods.methods: this study was performed on 50 formalin-fixed paraffin-embedded (ffpe)tissue blocks of patients diagnosed with colorectal cancer. after dna extraction, krasand braf gene mutations were evaluated using reverse dot blot, and results werecompared with pcr-rflp and allele-specific pcr for kras and braf mutations, respectively.results: kras gene mutations were detected in 42% of patients, of which 30% were incodon 12 region, and 12% in codon 13. the most frequent mutations of kras were relatedto g12d and 10% of patients had braf mutated genes. the type of kras genemutations could be evaluated by reverse dot blot method. in general, the results ofpcr-rflp and allele-specific pcr were similar to the findings by reverse dot blotmethod.conclusion: these findings suggest that pcr-rflp and allele-specific pcr methodsare suitable for screening the presence of the mutations in kras and braf oncogenes.in fact, another method with more sensitivity is needed for a more accurate assessmentto determine the type of mutations. due to higher speed of detection, reducedturnaround time (tat), and possible role of some kras point mutations inoverall survival, reverse dot blot analysis seems to be an optimal method.